1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Jiaxin Niu, Adnan Nagrial, Mark Voskoboynik, Hyun Cheol Chung, D.H. Lee, M-J. Ahn, Todd M. Bauer, Antonio Jimeno, Vincent Chung, Kathryn F. Mileham, Elliot Chartash, D. Chen, Jane Healy, Mohini Rajasagi, Corinne Maurice‐Dror
Topics & Concepts
PembrolizumabMedicineTIGITTolerabilityInternal medicineAtezolizumabOncologyAdverse effectPopulationNivolumabPhases of clinical researchGastroenterologyCancerImmunotherapyChemotherapyEnvironmental healthCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesCAR-T cell therapy research